Reduction in cardiovascular disease morbidity of men and women with familial hypercholesterolaemia (FH) associated with availability of high intensity statins: A cohort study using data from the UK Simon Broome Register linked with secondary care records

Reduction in cardiovascular disease morbidity of men and women with familial hypercholesterolaemia (FH) associated with availability of high intensity statins: A cohort study using data from the UK Simon Broome Register linked with secondary care records

Bibliographic Details
Main Authors:	B. Iyen, N. Qureshi, P. Roderick, N. Capps, P.N. Durrington, I.F.W. McDowell, J. Cegla, H. Soran, J. Schofield, H.A.W. Neil, J. Kai, S. Weng, S.E. Humphries
Format:	Article
Language:	English
Published:	Elsevier 2021-09-01
Series:	Atherosclerosis Plus
Online Access:	http://www.sciencedirect.com/science/article/pii/S2667089521000122

Similar Items

Cardiovascular disease morbidity is associated with social deprivation in subjects with familial hypercholesterolaemia (FH): a study comparing FH individuals in UK primary care and the UK Simon Broome register linked with secondary care records
by: B. Iyen, et al.
Published: (2022-10-01)

Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study
by: Neil, A, et al.
Published: (2008)

Does socioeconomic status have an effect on the treatment and outcomes of individuals with familial hypercholesterolaemia (FH)? : a cohort study of individuals with FH in UK primary care
by: B. Iyen, et al.
Published: (2021-09-01)

Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study.
by: Neil, A, et al.
Published: (2008)

Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group.
by: Neil, H, et al.
Published: (1999)

Elevated lipoprotein(a) levels in Familial Hypercholesterolaemia (FH): prevalence and implications for FH clinical diagnosis
by: A. David, et al.
Published: (2023-12-01)

NOVEL INFLAMMATORY RISK MARKERS INCLUDING LPPLA2 AND RISK OF CHD IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA (FH)
by: Seed, M, et al.
Published: (2009)

NOVEL INFLAMMATORY RISK MARKERS INCLUDING LPPLA2 AND RISK OF CHD IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA (FH)
by: Seed, M, et al.
Published: (2009)

CURRENT STATIN TREATMENT OF PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA (FH): RESULTS FROM THE ROYAL COLLEGE OF PHYSICIANS UK NATIONAL AUDIT
by: Seed, M, et al.
Published: (2011)

Non-coronary heart disease mortality and risk of fatal cancer in patients with treated heterozygous familial hypercholesterolaemia: a prospective registry study.
by: Neil, H, et al.
Published: (2005)

Statins and familial hypercholesterolaemia.
by: Neil, A, et al.
Published: (2009)

Modelling a two-stage screen for autosomal dominant familial hypercholesterolaemia (FH) in UK Biobank
by: J. Gratton, et al.
Published: (2022-10-01)

How many individuals with Familial Hypercholesterolaemia (FH) need to be identified to achieve the NHS 2019 Long Term Plan ambition?
by: S.E. Humphries, et al.
Published: (2023-12-01)

Prevalence of familial hypercholesterolaemia (FH)-causing variants and impact on LDL-C concentration in European, South Asian, and African ancestry groups of the UK Biobank
by: J. Gratton, et al.
Published: (2023-12-01)

How many homozygous Familial Hypercholesterolaemia (FH) patients are there likely to be in the UK? : The FH phenotype caused by the APOB p.(Arg3527Trp) variant in a South Asian family
by: I. Tracey, et al.
Published: (2022-10-01)

A novel combinatorial non-viral vector to treat familial hypercholesterolaemia (FH)
by: Kerr, A, et al.
Published: (2016)

Identification of FH-causing variants in patients with clinical familial hypercholesterolaemia recruited into the 100,000 genome project: preliminary analysis
by: A. Rimbert, et al.
Published: (2021-09-01)

Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation
by: P Sharma, et al.
Published: (2012-03-01)

Controversies in familial hypercholesterolaemia: recommendations of the NICE Guideline Development Group for the identification and management of familial hypercholesterolaemia.
by: Minhas, R, et al.
Published: (2009)

Children and young adults with familial hypercholesterolaemia (FH) have healthier food choices particularly with respect to dietary fat sources compared with non-FH children
by: Ingunn Molven, et al.
Published: (2013-01-01)

A novel mutation in exon 5 of the low density lipoprotein receptor gene in a Malay family with familial hypercholesterolaemia (FH)
by: Abdul Murad N. A.,, et al.
Published: (2013)

19. Using a novel combinatorial non-viral vector and small molecules to treat familial hypercholesterolaemia (FH)
by: Kerr, A, et al.
Published: (2016)

The utility of DNA-based testing in patients with familial hypercholesterolaemia in the UK
by: Humphries, SE, et al.
Published: (2005)

Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia
by: Neil, A, et al.
Published: (2003)

Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia.
by: Neil, H, et al.
Published: (2004)

Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia
by: Neil, H, et al.
Published: (2003)

All-cause and cardiovascular mortality in treated patients with severe hypertriglyceridaemia: A long-term prospective registry study.
by: Neil, H, et al.
Published: (2010)

Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis.
by: Marks, et al.
Published: (2000-01-01)

The development of a theory informed behaviour change intervention to improve adherence to dietary and physical activity treatment guidelines in individuals with familial hypercholesterolaemia (FH)
by: F. J. Kinnear, et al.
Published: (2020-01-01)

The effect of adjusting LDL-cholesterol for Lipoprotein(a)-cholesterol on the diagnosis of Familial Hypercholesterolaemia
by: D. Thayabaran, et al.
Published: (2022-10-01)

Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis.
by: Marks, D, et al.
Published: (2000)

Comparison of the risk of fatal coronary heart disease in treated xanthomatous and non-xanthomatous heterozygous familial hypercholesterolaemia: a prospective registry study.
by: Neil, H, et al.
Published: (2003)

Lomitapide hepatic safety: A long-term retrospective analysis in patients with homozygous familial hypercholesterolaemia
by: J. Cegla, et al.
Published: (2023-12-01)

Effect of statin treatment for familial hypercholesterolaemia on life assurance: results of consecutive surveys in 1990 and 2002.
by: Neil, H, et al.
Published: (2004)

Treatment of familial hypercholesterolaemia. United Kingdom lipid clinics study of pravastatin and cholestyramine.
by: Betteridge, D, et al.
Published: (1992)

Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia.
by: Nherera, L, et al.
Published: (2010)

Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk.
by: Humphries, SE, et al.
Published: (2006)

Familial hypercholesterolaemia.
by: Gill, P, et al.
Published: (2012)

A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia.
by: Marks, D, et al.
Published: (2003)

Familial Hypercholesterolaemia – a targeted Next Generation Sequencing panel and retrospective analysis of patients with no previously identified pathogenic variant
by: E. Willis, et al.
Published: (2022-10-01)